Oleoylethanolamine (OEA) is a naturally occurring ethanolamide lipid and a nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) agonist. It is produced in the small intestine and inhibits food intake via PPAR-α activation. OEA also activates GPR119, a bioactive lipid with hypophagic and anti-obesity effects.
|Synonyms||N-Oleoylethanolamine, N-(Hydroxyethyl)oleamide, N-(cis-9-Octadecenoyl)ethanolamine, OEA|
|Melting Point||59–60 °C (138–140 °F; 332–333 K)|
|Solubility||H2O : < 0.1 mg/mL (insoluble); DMSO : 20.83 mg/mL (63.99 mM; Need ultrasonic|
|Application||N-Oleoylethanolamine has been used to study its effects on glucagon-like peptide (GLP)-1RA-mediated anorectic signaling and weight loss.|
OEA is a highly concentrated metabolite of olive oil. RiduZone was designed to harness the benefits of mediterranean food and to help support weight loss.
RiduZone (OEA Capsule) is accepted by the FDA as a new dietary supplement.
OEA is a natural regulator of appetite, weight and cholesterol.
Oleoylethanolamide (OEA) is a natural metabolite that is made in small amounts in your small intestine. OEA helps regulate hunger, weight, body fat and cholesterol by binding to a receptor known as PPAR-Alpha (Peroxisome proliferator-activated receptor alpha). In essence, OEA increases the metabolism of body fat and tells your brain that you are full and it’s time to stop eating. OEA is also known to increase non-exercise related calorie expenditure.
Oleoylethanolamide’s biological functions were discovered as early as 50 years ago. Before 2001, there wasn’t much research on OEA. However, that year, Spanish researchers broke down the lipid and studied how it’s made, where it’s used and what it does. They tested the effect of OEA on the brain (of rats) by injecting it directly into the brain ventricles. They found no effect on eating and confirmed that OEA does not act in the brain, but rather, it triggers a separate signal that affects hunger and eating behavior.
To put it simply, oleoylethanolamide works as a hunger regulator. OEA is able to control your food intake by telling the brain that the body is full, and no more food is needed. You eat less every day, and your body may be not overweight in the long run.
The anti-obesity actions of oleoylethanolamide (OEA) is as shown in the picture. OEA is synthesized and mobilized in the proximal small intestine from diet-derived oleic acid, such as olive oils. High-fat diet can inhibit OEA production in the intestine. OEA reduces food intake by activating homeostatic oxytocin and histamine brain circuitry as well as hedonic dopamine pathways. There is evidence that OEA may also attenuate hedonic cannabinoid receptor 1 (CB1R) signaling, the activation of which is associated with increased food intake. OEA reduces lipid transport into adipocytes to decrease fat mass. Further elucidation of the effects of OEA on food intake and lipid metabolism will aid in the determination of physiological mechanisms that can be targeted to develop more effective obesity therapies.
OEA works to activate something called PPAR and simultaneously ramps up fat-burning and decreases fat storage. When you eat, OEA levels increase and your appetite decreases when the sensory nerves that link to your brain tell it that you’re full. PPAR-α is a group of ligand-activated nuclear receptor that involved in the gene expression of lipid metabolism and energyhomeostasis pathways.
OEA shows all of the defining characteristics of a satiety factor:
(1) It inhibits feeding by prolonging the interval to the next meal;
(2) Its synthesis is regulated by nutrient availability and
(3) Its levels undergo circadian fluctuations.
N-Oleoylethanolamide is an agonist of peroxisome proliferator-activated receptor-α (PPAR-α). N-Oleoylethanolamide generates an intestinal signal that stimulates central dopamine activity establishing a link between caloric-homeostatic and hedonic-homeostatic controllers. Oleoylethanolamide has been implicated as the molecular mechanism associated with gastric bypass success. N-Oleoylethanolamide is a selective GPR55 agonist.
In one study, fifty (n=50) human subjects interested in losing weight were advised to take OEA 2-3 times/day, 15-30 minutes before a meal for 4-12 weeks. Subjects included those who had not used weight loss products before, those who experienced adverse events with other weight loss products, those whose weight loss plateaued on other weight loss agents such as phentermine, those trying to implement life style changes (portion control and regular exercise), and those actively being managed for medical conditions including impaired glucose tolerance, dyslipidemia, hypertension and cardiovascular diseases.
In a second study, 4 subjects with baseline weights of 229, 242, 375 and 193 lbs respectively, were instructed to take the Oleoylethanolamide capsules (one capsule containing 200mg 90% OEA). Subjects took 4 capsules (1 capsule 15-30 minutes before meals and they were to take an extra capsule prior to their largest meal of the day) daily for 28 days. The last subject had previously undergone lap band placement. Subjects were instructed to make no changes to their diet and exercise habits.